SEA Deal Ticker
Southeast Asia rarely funds frontier cancer biotech: Singapore's Tikva Allocell raises $8M toward an IND
The Series A, led by Kantharos Capital, funds IND-enabling work on an off-the-shelf cell therapy for B7-H3-positive solid tumours, with a regulatory submission planned for year-end 2026.
Positive-sum angle: A cell-therapy platform licensed from Baylor and built out in Singapore gives the region a path to manufacturing cancer treatments locally, not importing every breakthrough.